This article summarized the latest R&D progress of Fezolinetant, the Mechanism of Action for Fezolinetant, and the drug target R&D trends for Fezolinetant.
This article summarized the latest R&D progress of Entrectinib, the Mechanism of Action for Entrectinib, and the drug target R&D trends for Entrectinib.
Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.
This article summarized the latest R&D progress of Daprodustat, the Mechanism of Action for Daprodustat, and the drug target R&D trends for Daprodustat.
This article summarized the latest R&D progress of Colecalciferol, the Mechanism of Action for Colecalciferol, and the drug target R&D trends for Colecalciferol.
Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.